Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts

Terutoshi Yamaoka, Yoshikazu Yonemitsu, Kimihiro Komori, Hiromitsu Baba, takuya matsumoto, Toshihiro Onohara, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gene transfer to vein grafts has therapeutic potential to prevent late graft failure; however, certain issues, including efficacy and safety, have hindered the clinical application of this treatment modality. Here, we report the successful and efficient gene transfer of plasmid DNA via ex vivo electroporation into veins as well as into vein grafts. Two approaches were used: one involved transluminal in situ gene transfer using a T-shaped electrode (the "Lu" method), and the other was an adventitial ex vivo approach using an electroporation cuvette followed by vein grafting (the "Ad" method). The Lu method was carried out at 10 V, with optimal gene transfer efficiency in the in situ jugular veins of rabbits, and transgene expression was observed primarily in endothelial cells. However, when these veins were grafted into the arterial circulation, no luciferase activity was detected; this effect was probably due to the elimination of the gene-transferred cells as a result of endothelial denudation. In contrast, optimal and satisfactory gene transfer was obtained with the vein grafts subjected to the Ad method at 30 V, and transgene expression was seen primarily in adventitial fibroblasts. Gene transfer of endothelial nitric oxide synthase cDNA to the vein graft via the Ad method successfully limited the extent of intimal hyperplasia, even under hyperlipidemic conditions, at 4 wk after grafting. We thus propose that the Ad method via ex vivo electroporation may provide a novel, safe, and clinically available technique for nonviral gene transfer to sufficiently prevent late graft failure.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume289
Issue number5 58-5
DOIs
Publication statusPublished - Nov 1 2005

Fingerprint

Electroporation
Veins
Transplants
Genes
Adventitia
Transgenes
Tunica Intima
Gene Transfer Techniques
Nitric Oxide Synthase Type III
Jugular Veins
Luciferases
Hyperplasia
Electrodes
Plasmids
Endothelial Cells
Complementary DNA
Fibroblasts
Rabbits
Safety
DNA

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts. / Yamaoka, Terutoshi; Yonemitsu, Yoshikazu; Komori, Kimihiro; Baba, Hiromitsu; matsumoto, takuya; Onohara, Toshihiro; Maehara, Yoshihiko.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 289, No. 5 58-5, 01.11.2005.

Research output: Contribution to journalArticle

Yamaoka, Terutoshi ; Yonemitsu, Yoshikazu ; Komori, Kimihiro ; Baba, Hiromitsu ; matsumoto, takuya ; Onohara, Toshihiro ; Maehara, Yoshihiko. / Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts. In: American Journal of Physiology - Heart and Circulatory Physiology. 2005 ; Vol. 289, No. 5 58-5.
@article{4e00cfd4a4214f73956a936488be0286,
title = "Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts",
abstract = "Gene transfer to vein grafts has therapeutic potential to prevent late graft failure; however, certain issues, including efficacy and safety, have hindered the clinical application of this treatment modality. Here, we report the successful and efficient gene transfer of plasmid DNA via ex vivo electroporation into veins as well as into vein grafts. Two approaches were used: one involved transluminal in situ gene transfer using a T-shaped electrode (the {"}Lu{"} method), and the other was an adventitial ex vivo approach using an electroporation cuvette followed by vein grafting (the {"}Ad{"} method). The Lu method was carried out at 10 V, with optimal gene transfer efficiency in the in situ jugular veins of rabbits, and transgene expression was observed primarily in endothelial cells. However, when these veins were grafted into the arterial circulation, no luciferase activity was detected; this effect was probably due to the elimination of the gene-transferred cells as a result of endothelial denudation. In contrast, optimal and satisfactory gene transfer was obtained with the vein grafts subjected to the Ad method at 30 V, and transgene expression was seen primarily in adventitial fibroblasts. Gene transfer of endothelial nitric oxide synthase cDNA to the vein graft via the Ad method successfully limited the extent of intimal hyperplasia, even under hyperlipidemic conditions, at 4 wk after grafting. We thus propose that the Ad method via ex vivo electroporation may provide a novel, safe, and clinically available technique for nonviral gene transfer to sufficiently prevent late graft failure.",
author = "Terutoshi Yamaoka and Yoshikazu Yonemitsu and Kimihiro Komori and Hiromitsu Baba and takuya matsumoto and Toshihiro Onohara and Yoshihiko Maehara",
year = "2005",
month = "11",
day = "1",
doi = "10.1152/ajpheart.00353.2005",
language = "English",
volume = "289",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5 58-5",

}

TY - JOUR

T1 - Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts

AU - Yamaoka, Terutoshi

AU - Yonemitsu, Yoshikazu

AU - Komori, Kimihiro

AU - Baba, Hiromitsu

AU - matsumoto, takuya

AU - Onohara, Toshihiro

AU - Maehara, Yoshihiko

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Gene transfer to vein grafts has therapeutic potential to prevent late graft failure; however, certain issues, including efficacy and safety, have hindered the clinical application of this treatment modality. Here, we report the successful and efficient gene transfer of plasmid DNA via ex vivo electroporation into veins as well as into vein grafts. Two approaches were used: one involved transluminal in situ gene transfer using a T-shaped electrode (the "Lu" method), and the other was an adventitial ex vivo approach using an electroporation cuvette followed by vein grafting (the "Ad" method). The Lu method was carried out at 10 V, with optimal gene transfer efficiency in the in situ jugular veins of rabbits, and transgene expression was observed primarily in endothelial cells. However, when these veins were grafted into the arterial circulation, no luciferase activity was detected; this effect was probably due to the elimination of the gene-transferred cells as a result of endothelial denudation. In contrast, optimal and satisfactory gene transfer was obtained with the vein grafts subjected to the Ad method at 30 V, and transgene expression was seen primarily in adventitial fibroblasts. Gene transfer of endothelial nitric oxide synthase cDNA to the vein graft via the Ad method successfully limited the extent of intimal hyperplasia, even under hyperlipidemic conditions, at 4 wk after grafting. We thus propose that the Ad method via ex vivo electroporation may provide a novel, safe, and clinically available technique for nonviral gene transfer to sufficiently prevent late graft failure.

AB - Gene transfer to vein grafts has therapeutic potential to prevent late graft failure; however, certain issues, including efficacy and safety, have hindered the clinical application of this treatment modality. Here, we report the successful and efficient gene transfer of plasmid DNA via ex vivo electroporation into veins as well as into vein grafts. Two approaches were used: one involved transluminal in situ gene transfer using a T-shaped electrode (the "Lu" method), and the other was an adventitial ex vivo approach using an electroporation cuvette followed by vein grafting (the "Ad" method). The Lu method was carried out at 10 V, with optimal gene transfer efficiency in the in situ jugular veins of rabbits, and transgene expression was observed primarily in endothelial cells. However, when these veins were grafted into the arterial circulation, no luciferase activity was detected; this effect was probably due to the elimination of the gene-transferred cells as a result of endothelial denudation. In contrast, optimal and satisfactory gene transfer was obtained with the vein grafts subjected to the Ad method at 30 V, and transgene expression was seen primarily in adventitial fibroblasts. Gene transfer of endothelial nitric oxide synthase cDNA to the vein graft via the Ad method successfully limited the extent of intimal hyperplasia, even under hyperlipidemic conditions, at 4 wk after grafting. We thus propose that the Ad method via ex vivo electroporation may provide a novel, safe, and clinically available technique for nonviral gene transfer to sufficiently prevent late graft failure.

UR - http://www.scopus.com/inward/record.url?scp=27144491600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144491600&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00353.2005

DO - 10.1152/ajpheart.00353.2005

M3 - Article

C2 - 16219811

AN - SCOPUS:27144491600

VL - 289

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 5 58-5

ER -